Suchergebnisse - "Bonnett, Tyler"

PubPharm (20)

1

SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2024

von Laverdure, S. | Kazadi, D. | Kone, K. | +66

2

A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19 : A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

enthalten in: Annals of internal medicine | 2024

von Paules, C. | Wang, J. | Tomashek, K. | +18

3

Effects of remdesivir in patients hospitalised with COVID-19 : a systematic review and individual patient data meta-analysis of randomised controlled trials

enthalten in: The Lancet. Respiratory medicine | 2023

von Amstutz, A. | Speich, B. | Mentré, F. | +32

CommentIn: Lancet Respir Med. 2023 May;11(5):397-398. - PMID 36828007

4

Counting Monkeypox Lesions in Patient Photographs : Limits of Agreement of Manual Counts and Artificial Intelligence

enthalten in: The Journal of investigative dermatology | 2023

von McNeil, A. | House, D. | Mbala-Kingebeni, P. | +9

5

Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults : A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial

enthalten in: Annals of internal medicine | 2022

von Potter, G. | Bonnett, T. | Rubenstein, K. | +41

6

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4) : a randomised, double-blind, double placebo-controlled trial

enthalten in: The Lancet. Respiratory medicine | 2022

von Wolfe, C. | Tomashek, K. | Patterson, T. | +162

CommentIn: Ann Intern Med. 2022 Oct;175(10):JC115. - PMID 36191322

7

Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients : Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2

enthalten in: Open forum infectious diseases | 2022

von Fintzi, J. | Bonnett, T. | Tebas, P. | +16

8

Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 : Implications for Critical Care Resource Utilization

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Fintzi, J. | Bonnett, T. | Sweeney, D. | +7

9

Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)

enthalten in: PloS one | 2022

von Sereti, I. | Shaw-Saliba, K. | Dodd, L. | +51

10

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19 : a double-bind, randomised, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Kalil, A. | Mehta, A. | Patterson, T. | +154

CommentIn: Lancet Respir Med. 2021 Dec;9(12):1344-1345. - PMID 34672951